Caplin Point Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Caplin Point Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 13.6% bzw. 13.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.6% betragen.

Wichtige Informationen

13.6%

Wachstumsrate der Gewinne

13.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.6%
Wachstumsrate der Einnahmen	13.2%
Zukünftige Eigenkapitalrendite	18.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	20 Jan 2025

Jüngste Aktualisierungen zum künftigen Wachstum

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Nov 10

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Aug 11

Recent updates

Some Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Shareholders Look For Exit As Shares Take 27% Pounding

Jan 28

Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is Lacking

Dec 01

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Nov 10

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 31

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

Sep 12

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Aug 11

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

Aug 10

Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Jul 12

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

May 24

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

May 04

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Mar 07

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 24

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Sep 15

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Aug 11

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Sep 23

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Sep 11

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Jul 22

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00

May 15

A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Jan 21

Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?

Oct 20

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50

Sep 17

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50

Sep 03

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price

Aug 27

Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?

Jun 12

Gewinn- und Umsatzwachstumsprognosen

NSEI:CAPLIPOINT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	25,604	7,061	5,040	5,119	1
3/31/2026	22,369	5,806	4,138	5,220	3
3/31/2025	19,665	5,069	3,174	4,027	3
9/30/2024	18,328	4,936	2,310	3,748	N/A
6/30/2024	17,577	4,776	N/A	N/A	N/A
3/31/2024	16,961	4,571	1,726	3,184	N/A
12/31/2023	16,318	4,376	N/A	N/A	N/A
9/30/2023	15,683	4,179	399	2,593	N/A
6/30/2023	15,157	3,947	N/A	N/A	N/A
3/31/2023	14,683	3,763	779	2,714	N/A
12/31/2022	14,182	3,532	N/A	N/A	N/A
9/30/2022	13,724	3,307	2,305	3,467	N/A
6/30/2022	13,153	3,140	N/A	N/A	N/A
3/31/2022	12,710	2,998	2,456	3,367	N/A
12/31/2021	12,099	2,872	N/A	N/A	N/A
9/30/2021	11,581	2,767	1,288	2,044	N/A
6/30/2021	11,217	2,586	N/A	N/A	N/A
3/31/2021	10,624	2,423	1,953	2,686	N/A
12/31/2020	9,986	2,248	N/A	N/A	N/A
9/30/2020	9,524	2,189	1,650	1,877	N/A
6/30/2020	9,107	2,193	N/A	N/A	N/A
3/31/2020	8,640	2,150	-321	447	N/A
12/31/2019	8,356	2,159	N/A	N/A	N/A
9/30/2019	7,664	2,032	-331	830	N/A
6/30/2019	6,948	1,894	N/A	N/A	N/A
3/31/2019	6,490	1,766	182	834	N/A
12/31/2018	6,048	1,621	N/A	N/A	N/A
9/30/2018	5,874	1,538	N/A	N/A	N/A
6/30/2018	5,628	1,459	N/A	N/A	N/A
3/31/2018	5,399	1,448	N/A	665	N/A
12/31/2017	5,145	1,430	N/A	N/A	N/A
9/30/2017	4,757	1,297	N/A	N/A	N/A
6/30/2017	4,401	1,165	N/A	N/A	N/A
3/31/2017	4,016	956	N/A	676	N/A
12/31/2016	3,655	783	N/A	N/A	N/A
9/30/2016	3,420	703	N/A	N/A	N/A
6/30/2016	3,238	619	N/A	N/A	N/A
3/31/2016	3,088	584	N/A	565	N/A
12/31/2015	2,906	535	N/A	N/A	N/A
9/30/2015	2,722	465	N/A	N/A	N/A
6/30/2015	2,518	410	N/A	499	N/A
3/31/2015	2,296	353	N/A	N/A	N/A
12/31/2014	2,074	318	N/A	N/A	N/A
9/30/2014	1,893	305	N/A	N/A	N/A
6/30/2014	1,731	258	N/A	598	N/A
3/31/2014	1,643	204	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CAPLIPOINTDas prognostizierte Gewinnwachstum (13.6% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: CAPLIPOINTDie Erträge des Unternehmens (13.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (17.9% pro Jahr).

Hohe Wachstumserträge: CAPLIPOINTDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: CAPLIPOINTDie Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.9% pro Jahr).

Hohe Wachstumseinnahmen: CAPLIPOINTDie Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CAPLIPOINTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.6%).

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/01/30 00:54
Aktienkurs zum Tagesende	2025/01/30 00:00
Gewinne	2024/09/30
Jährliche Einnahmen	2024/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

Caplin Point Laboratories Limited wird von 2 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Rohit Bhat	Batlivala & Karani Securities India Pvt. Ltd.
Siddhant Khandekar	ICICIdirect.com

Caplin Point Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Price target increased by 14% to ₹2,142

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Price target increased by 17% to ₹1,717

Price target increased by 8.0% to ₹1,076

Price target increased to ₹948

Recent updates

Some Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Shareholders Look For Exit As Shares Take 27% Pounding

Caplin Point Laboratories Ltd. Receives Establishment Inspection Report from the U.S. Food and Drug Administration

Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is Lacking

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Caplin Point Laboratories Limited Announces Cessation of D Sathyanarayanan as an Independent Director

Second quarter 2025 earnings released: EPS: ₹17.22 (vs ₹15.13 in 2Q 2024)

Caplin Point Laboratories Limited to Report Q2, 2025 Results on Nov 07, 2024

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Price target increased by 14% to ₹2,142

Upcoming dividend of ₹2.50 per share

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 19%

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

Price target increased by 17% to ₹1,717

Dividend of ₹2.50 announced

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024

Caplin Point Laboratories Limited to Report Q1, 2025 Results on Aug 07, 2024

Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer

Investor sentiment improves as stock rises 18%

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

Full year 2024 earnings: Revenues in line with analyst expectations

Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited to Report Fiscal Year 2024 Results on May 16, 2024

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Third quarter 2024 earnings released: EPS: ₹15.44 (vs ₹12.86 in 3Q 2023)

Caplin Point Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024

Investor sentiment improves as stock rises 16%

Price target increased by 8.0% to ₹1,076

Second quarter 2024 earnings released: EPS: ₹15.13 (vs ₹12.09 in 2Q 2023)

Caplin Point Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Upcoming dividend of ₹2.50 per share at 0.5% yield

Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023

Investor sentiment improves as stock rises 15%

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

First quarter 2024 earnings released: EPS: ₹13.62 (vs ₹11.21 in 1Q 2023)

Caplin Point Laboratories Limited to Report Q1, 2024 Results on Aug 07, 2023

Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP

Upcoming dividend of ₹2.00 per share at 0.3% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Caplin Point Laboratories Limited to Report Q4, 2023 Results on May 24, 2023

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: ₹12.86 (vs ₹9.90 in 3Q 2022)

Caplin Point Laboratories Limited to Report Q3, 2023 Results on Feb 11, 2023

Price target increased to ₹948

Caplin Point Laboratories Limited (BSE:524742) acquired API plant in Vizag from Metrochem API Private Limited.

Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)

Caplin Point Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022

Caplin Point Laboratories Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited Announces Change in Directorate

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Upcoming dividend of ₹2.00 per share

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released: EPS: ₹11.21 (vs ₹9.37 in 1Q 2022)

Caplin Point Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Caplin Point Laboratories Limited Announces Resignation of D P Mishra as Non-Executive, Non-Independent Director